Advertisement

The clinical value of texture analysis of dual-time-point 18F-FDG-PET/CT imaging to differentiate between 18F-FDG-avid benign and malignant pulmonary lesions

  • Masatoyo NakajoEmail author
  • Megumi Jinguji
  • Masaya Aoki
  • Atsushi Tani
  • Masami Sato
  • Takashi Yoshiura
Nuclear Medicine
  • 35 Downloads

Abstract

Objectives

To examine whether the texture analysis of dual-time-point (DTP) F-18-fluorodeoxyglucose (18F-FDG)-PET/CT imaging can differentiate between 18F-FDG-avid benign and malignant pulmonary lesions.

Methods

We compared standardized uptake value (SUV)-related (SUVmax [g/ml] and SUVmean [g/ml]), volumetric (metabolic tumor volume [MTV] [cm3] and total lesion glycolysis [TLG] [g]), and texture (entropy, homogeneity, dissimilarity, intensity variability [IV], size-zone variability [SZV], and zone percentage [ZP]) (MTV ≥ 5.0 cm3 and SUV ≥ 2.5 g/ml) parameters between 13 benign and 46 malignant lesions using the Mann–Whitney U test. Diagnostic performance was evaluated by receiver operating characteristic (ROC) analysis. Stepwise logistic regression analysis was performed to identify and use the independent variables that correctly differentiate between benign and malignant lesions.

Results

Malignant pulmonary lesions showed significantly higher SUVmax, SUVmean, MTV, TLG, entropy, dissimilarity, IV, and SZV and significantly lower homogeneity and ZP than benign pulmonary lesions (all p < 0.05) in both early and delayed images. Their areas under the ROC curves (AUCs) ranged between 0.69 and 0.94, and diagnostic accuracies between 64.4% and 93.2%. Entropy-early (p = 0.014), SUVmean-delay (p = 0.039), and dissimilarity-delay (p = 0.027) were independent parameters, and combined use of them yielded the highest AUC (0.98) with 100% sensitivity (46/46), 84.6% specificity (11/13), and 96.7% (57/59) accuracy for distinguishing between benign and malignant lesions.

Conclusions

The individual early and delayed SUV-related, volumetric, and texture parameters showed a wide range of accuracy. Combined use of independent parameters extracted from DTP imaging might yield a high diagnostic accuracy with balanced sensitivity and specificity to differentiate between benign and malignant 18F-FDG-avid pulmonary lesions.

Key Points

• Malignant pulmonary lesions showed significantly higher SUV-related (SUVmax and SUVmean) and volumetric (MTV and TLG) parameters than benign pulmonary lesions in both early and delayed images.

• Malignant pulmonary lesions showed significantly more heterogeneous 18 F-FDG uptake than benign pulmonary lesions in both early and delayed images.

• Combined use of independent parameters extracted from DTP imaging might yield a high diagnostic accuracy to differentiate between benign and malignant 18 F-FDG-avid pulmonary lesions.

Keywords

Lung neoplasm 18F-FDG Positron emission tomography computed tomography Differential diagnosis 

Abbreviations

BSA

Body surface area

CI

Confidence interval

DTP

Dual-time-point

FWHM

Full-width half-maximum

IV

Intensity variability

LBM

Lean body mass

MTV

Metabolic tumor volume

STP

Single-time-point

SUV

Standardized uptake value

SZV

Size-zone variability

TLG

Total lesion glycolysis

VOI

Volume of interest

ZP

Zone percentage

Notes

Acknowledgments

We thank Tetsuya Shinaji (Department of Nuclear Medicine, University of Würzburg) for the technical support for performing texture analysis. We also thank Prof. Chihaya Koriyama, of the Department of Epidemiology and Preventive Medicine, Kagoshima University, for the validation of the statistical analysis.

Funding information

The authors state that this work has not received any funding.

Compliance with ethical standards

Guarantor

The scientific guarantor of this publication is T. Yoshiura.

Conflict of interest

The authors declare that they have no competing interests.

Statistics and biometry

No complex statistical methods were necessary for this paper.

Informed consent

Written informed consent was waived by the Institutional Review Board.

Ethical approval

Institutional Review Board approval was obtained.

Methodology

• retrospective

• diagnostic or prognostic study

• performed at one institution

Supplementary material

330_2019_6463_MOESM1_ESM.docx (32 kb)
ESM 1 (DOCX 32 kb)

References

  1. 1.
    Gupta NC, Frank AR, Dewan NA et al (1992) Solitary pulmonary nodules: detection of malignancy with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 184:441–444CrossRefGoogle Scholar
  2. 2.
    Patz EF Jr, Lowe VJ, Hoffman JM et al (1993) Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 188:487–490CrossRefGoogle Scholar
  3. 3.
    Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 85:914–924CrossRefGoogle Scholar
  4. 4.
    Kapucu LO, Meltzer CC, Townsend DW, Keenan RJ, Luketich JD (1998) Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med 39:1267–1269PubMedGoogle Scholar
  5. 5.
    Goo JM, Im JG, Do KH et al (2000) Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216:117–121CrossRefGoogle Scholar
  6. 6.
    Igai H, Gotoh M, Yokomise H (2006) Computed tomography (CT) and positron emission tomography with [18F] fluoro-2-deoxy-D-glucose (FDG-PET) images of pulmonary cryptococcosis mimicking lung cancer. Eur J Cardiothorac Surg 30:837–839CrossRefGoogle Scholar
  7. 7.
    Nguyen NC, Kaushik A, Wolverson MK, Osman MM (2011) Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indication? A retrospective study. Acta Oncol 50:670–677CrossRefGoogle Scholar
  8. 8.
    Parghane RV, Basu S (2017) Dual-time point 18F-FDG-PET and PET/CT for differentiating benign from malignant musculoskeletal lesions: opportunities and limitations. Semin Nucl Med 47:373–391CrossRefGoogle Scholar
  9. 9.
    Matthies A, Hickeson M, Cuchiara A, Alavi A (2002) Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 43:871–875PubMedGoogle Scholar
  10. 10.
    Zhuang H, Pourdehnad M, Lambright ES et al (2001) Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412–1417PubMedGoogle Scholar
  11. 11.
    Xiu Y, Bhutani C, Dhurairaj T et al (2007) Dual-time point FDG PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity. Clin Nucl Med 32:101–105CrossRefGoogle Scholar
  12. 12.
    Suga K, Kawakami Y, Hiyama A et al (2009) Differential diagnosis between F-18-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan. Ann Nucl Med 23:523–531CrossRefGoogle Scholar
  13. 13.
    Cloran FJ, Banks KP, Song WS, Kim Y, Bradley YC (2010) Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Lung Cancer 68:66–71CrossRefGoogle Scholar
  14. 14.
    Kim DW, Park SA, Kim CG (2011) Dual-time-point positron emission tomography findings of benign mediastinal fluorine-18-fluorodeoxyglucose uptake in tuberculosis-endemic region. Indian J Nucl Med 26:3–6PubMedPubMedCentralGoogle Scholar
  15. 15.
    van Velden FH, Cheebsumon P, Yaqub M et al (2011) Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging 38:1636–1647CrossRefGoogle Scholar
  16. 16.
    El Naqa I, Grigsby P, Apte A et al (2009) Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern Recog 42:1162–1171CrossRefGoogle Scholar
  17. 17.
    Chen S, Harmon S, Perk T et al (2017) Diagnostic classification of solitary pulmonary nodules using dual time 18F-FDG PET/CT image texture features in granuloma-endemic regions. Sci Rep 7:9370CrossRefGoogle Scholar
  18. 18.
    Nakajo M, Nakajo M, Nakayama H et al (2016) Dexamethasone suppression FDG PET/CT for differentiating between true- and false-positive pulmonary and mediastinal lymph node metastases in non-small cell lung cancer: a pilot study of FDG PET/CT after oral administration of dexamethasone. Radiology 279:246–253CrossRefGoogle Scholar
  19. 19.
    Nakayama M, Okizaki A, Ishitoya S, Sakaguchi M, Sato J, Aburano T (2013) Dual-time point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesion. Ann Nucl Med 27:163–169CrossRefGoogle Scholar
  20. 20.
    Park SY, Cho A, Yu WS et al (2015) Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer. J Nucl Med 56:45–49CrossRefGoogle Scholar
  21. 21.
    Stahl A, Ott K, Schwaiger M, Weber WA (2004) Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 31:1471–1478CrossRefGoogle Scholar
  22. 22.
    Nakajo M, Jinguji M, Nakabeppu Y et al (2017) Texture analysis of 18F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy. Eur J Nucl Med Mol Imaging 44:206–214CrossRefGoogle Scholar
  23. 23.
    Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I (2014) Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med 55:414–422CrossRefGoogle Scholar
  24. 24.
    Soussan M, Orlhac F, Boubaya M et al (2014) Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. Plos One 9:e94017CrossRefGoogle Scholar
  25. 25.
    Youden WJ (1950) Index for rating diagnostic tests. Cancer 3:32–35CrossRefGoogle Scholar
  26. 26.
    DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845CrossRefGoogle Scholar
  27. 27.
    Barger RL Jr, Nandalur KR (2012) Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Acad Radiol 19:153–158CrossRefGoogle Scholar
  28. 28.
    Zhang L, Wang Y, Lei J, Tian J, Zhai Y (2013) Dual time point 18FDG-PET/CT versus single time point 18FDG-PET/CT for the differential diagnosis of pulmonary nodules: a meta-analysis. Acta Radiol 54:770–777CrossRefGoogle Scholar
  29. 29.
    Deppen SA, Blume JD, Kensinger CD et al (2014) Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA 312:1227–1236CrossRefGoogle Scholar
  30. 30.
    Lin YY, Chen JH, Ding HJ, Liang JA, Yeh JJ, Kao CH (2012) Potential value of dual-time-point 18F-FDG PET compared with initial single-time-point imaging in differentiating malignant from benign pulmonary nodules: a systematic review and meta-analysis. Nucl Med Commun 33:1011–1018CrossRefGoogle Scholar
  31. 31.
    Sollini M, Cozzi L, Antunovic L, Chiti A, Kirienko M (2017) PET radiomics in NSCLC: state of the art and a proposal for harmonization of methodology. Sci Rep 7:358CrossRefGoogle Scholar
  32. 32.
    Miwa K, Inubushi M, Wagatsuma K et al (2014) FDG uptake heterogeneity evaluated by fractal analysis improves the differential diagnosis of pulmonary nodules. Eur J Radiol 83:715–719CrossRefGoogle Scholar
  33. 33.
    Ha S, Choi H, Cheon GJ et al (2014) Autoclustering of non-small cell lung carcinoma subtypes on (18)F-FDG PET using texture analysis: a preliminary result. Nucl Med Mol Imaging 48:278–286CrossRefGoogle Scholar
  34. 34.
    Kim DH, Jung J, Son SH et al (2015) Prognostic significance of intratumoral metabolic heterogeneity on 18F-FDG PET/CT in pathological N0 non-small cell lung cancer. Clin Nucl Med 40:708–714CrossRefGoogle Scholar
  35. 35.
    Van de Wiele C, Kruse V, Smeets P, Sathekge M, Maes A (2013) Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. Eur J Nucl Med Mol Imaging 40:290–301CrossRefGoogle Scholar
  36. 36.
    Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1):122S–150SCrossRefGoogle Scholar
  37. 37.
    Fukukita H, Senda M, Terauchi T et al (2010) Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med 24:325–334CrossRefGoogle Scholar

Copyright information

© European Society of Radiology 2019

Authors and Affiliations

  • Masatoyo Nakajo
    • 1
    Email author
  • Megumi Jinguji
    • 1
  • Masaya Aoki
    • 2
  • Atsushi Tani
    • 1
  • Masami Sato
    • 2
  • Takashi Yoshiura
    • 1
  1. 1.Department of Radiology, Graduate School of Medical and Dental SciencesKagoshima UniversityKagoshimaJapan
  2. 2.Department of Thoracic Surgery, Graduate School of Medical and Dental SciencesKagoshima UniversityKagoshimaJapan

Personalised recommendations